Weekly Analysts’ Ratings Updates for Nyxoah (NYXH)

A number of firms have modified their ratings and price targets on shares of Nyxoah (NASDAQ: NYXH) recently:

• 5/22/2026 – Nyxoah was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 5/13/2026 – Nyxoah had its “overweight” rating reaffirmed by Piper Sandler. They now have a $7.00 price target on the stock, down from $9.00.
• 5/12/2026 – Nyxoah had its “hold” rating reaffirmed by Stifel Nicolaus. They now have a $5.00 price target on the stock, down from $8.00.
• 5/11/2026 – Nyxoah was upgraded by Weiss Ratings from “sell (e+)” to “sell (d-)”.
• 4/22/2026 – Nyxoah was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 4/10/2026 – Nyxoah had its price target lowered by Stifel Nicolaus from $10.00 to $8.00. They now have a “buy” rating on the stock.

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep‐disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.